We have located links that may give you full text access.
CLINICAL TRIAL
JOURNAL ARTICLE
MULTICENTER STUDY
RANDOMIZED CONTROLLED TRIAL
RESEARCH SUPPORT, NON-U.S. GOV'T
Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.
American Journal of Ophthalmology 2001 October
PURPOSE: To evaluate the effect of treatment with interferon beta-1a (Avonex) initiated at the time of a first episode of optic neuritis in patients at high risk for multiple sclerosis (MS).
DESIGN: Randomized clinical trial.
METHODS: Prospective.
SETTING: Fifty clinical centers throughout the US and Canada.
STUDY POPULATION: After the onset of a first episode of optic neuritis treated with intravenous and oral corticosteroids, 192 patients with brain magnetic resonance imaging (MRI) evidence of subclinical demyelination were randomly assigned to receive weekly intramuscular injections of 30 microg interferon beta-1a or placebo.
MAIN OUTCOME MEASURE: The study outcomes were the development of clinically definite MS within 3 years of follow-up and brain MRI changes at 6, 12, and 18 months.
RESULTS: The rates of clinically definite MS and of a combined MS/MRI outcome were lower in the interferon beta-1a group than in the placebo group (adjusted rate ratios 0.58, 95% confidence interval 0.34 to 1.00; and 0.50, 95% confidence interval 0.34 to 0.73, respectively). Compared with the placebo group, on the 18-month brain MRI the interferon beta-1a group had a smaller change from baseline in T2 lesion volume (P =.02), fewer new or enlarging T2 lesions (P <.001), and a lower frequency of Gd-enhancing lesions (P <.001).
CONCLUSION: The clinical and brain MRI results of this trial support initiating interferon beta-1a treatment at the time of a first episode of optic neuritis occurring in patients at high risk for MS based on the presence of subclinical brain MRI lesions.
DESIGN: Randomized clinical trial.
METHODS: Prospective.
SETTING: Fifty clinical centers throughout the US and Canada.
STUDY POPULATION: After the onset of a first episode of optic neuritis treated with intravenous and oral corticosteroids, 192 patients with brain magnetic resonance imaging (MRI) evidence of subclinical demyelination were randomly assigned to receive weekly intramuscular injections of 30 microg interferon beta-1a or placebo.
MAIN OUTCOME MEASURE: The study outcomes were the development of clinically definite MS within 3 years of follow-up and brain MRI changes at 6, 12, and 18 months.
RESULTS: The rates of clinically definite MS and of a combined MS/MRI outcome were lower in the interferon beta-1a group than in the placebo group (adjusted rate ratios 0.58, 95% confidence interval 0.34 to 1.00; and 0.50, 95% confidence interval 0.34 to 0.73, respectively). Compared with the placebo group, on the 18-month brain MRI the interferon beta-1a group had a smaller change from baseline in T2 lesion volume (P =.02), fewer new or enlarging T2 lesions (P <.001), and a lower frequency of Gd-enhancing lesions (P <.001).
CONCLUSION: The clinical and brain MRI results of this trial support initiating interferon beta-1a treatment at the time of a first episode of optic neuritis occurring in patients at high risk for MS based on the presence of subclinical brain MRI lesions.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app